Skip to main content

Home/ Health affairs/ Group items tagged cognitive

Rss Feed Group items tagged

bobby mac

cognitive behavioural therapy cbt - 0 views

  •  
    cognitive behavioural therapy cbt
pharmacybiz

Diabetes Duration Linked to Brain Structure Changes: Study - 0 views

  •  
    A study conducted by Michigan Medicine revealed that individuals who experience type 2 diabetes over an extended period are increasingly prone to experiencing alterations in their brain structure. A group of scientists examined data from 51 middle-aged Pima American Indians who were diagnosed with type 2 diabetes. They employed a set of memory and language assessments known as the NIH Toolbox Cognitive Battery, developed by the National Institutes of Health, alongside MRI scans. These analyses aimed to establish the connection between diabetes, cognitive function, and the composition of the brain. Brain imaging suggested that study participants with longer durations of type 2 diabetes had decreased mean cortical thickness and gray matter volumes, and an increased volume of white matter hyperintensities. The MRI results, researchers say, indicate the negative effects longstanding diabetes may have on brain health outcomes and emphasise the importance of preventing early onset type 2 diabetes.
pharmacybiz

Eli Lilly drug slows Alzheimer's by 35%:Company - 0 views

  •  
    An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.
fnfdoc

Risk Factors For Alzheimer's | Health Blog - 0 views

  •  
    Alzheimer's is a mental illness that mostly affects the elderly. It is characterized by dementia, cognitive impairment, and mood swings. The patient gradually fades into a state of perpetual darkness and lack of self-awareness. Here are some steps we can take to reduce our own risk.
  •  
    Scientists are trying to find ways to prevent Alzheimer's before it comes knocking at your doorstep. Extensive research is taking place even as you read this. Everyone hopes to put together the answer before it becomes a global issue. Here are a few risk factors that you can and can't avoid:
pharmacybiz

NICE Guidelines To Treat Depression In Adults - 0 views

  •  
    An independent committee at the National Institute for Health and Care Excellence (NICE) has developed a menu of options to treat depression in adults. The first guideline to identify, treat and manage depression has been created after looking at the evidence of treatment on various aspects of depression. The guideline allows patients to select the best suited cure for them through a shared decision-making process between them and their healthcare practitioner. Patients with less severe depression can choose a first-line treatment option from the menu, such as cognitive behavioural therapy (CBT), exercise, counselling or psychotherapy. Similarly, those with a severe depression can select from a range of psychological interventions and antidepressant medication. As per data released by the Office of National Statistics, around 17 per cent of people aged 16 years and over in Great Britain experienced some form of depression in summer 2021, higher than the previous year.
pharmacybiz

BlueIron : Lanes Health acquires distribution rights - 0 views

  •  
    With a trusted army of loyal fans on social media, the Nordic liquid iron supplement, BlueIron, is set for a refreshed look and big ambitions under a new distribution agreement. Lanes Health, the family-owned business known for its passion and expertise in manufacturing and supplying natural and herbal remedies, has acquired the distribution rights for the Finnish brand. As part of the deal, Lanes Health has been working to refresh the packaging and website, as well as developing a robust marketing campaign involving advertising, digital, social media, PR and influencer relations. A liquid iron supplement formulated with Nordic blueberries, BlueIron provides iron which is highly bioavailable and fast working. With the added benefit of a patented micro-encapsulated form of iron, it is easily absorbed and gentle on the stomach. Iron is an essential mineral used by our bodies for many health benefits, it is important for making red blood cells, transporting oxygen around the body, supporting energy metabolism, maintaining cognitive function and reducing tiredness and fatigue.
pharmacybiz

Lecanemab:Eisai Alzheimer's disease drug available next year - 0 views

  •  
    Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.
pharmacybiz

Assisted Living Facility :How To Choose The Right - 0 views

  •  
    Assisted living facilities are for people with cognitive decline or those with trouble managing their daily activities like feeding themselves, getting dressed, or bathing. If your loved one can't perform two or more basic daily activities, they become candidates for assisted living. Choosing an assisted living facility goes beyond just signing up and moving in. The choice should be carefully considered because this is where your loved ones will probably spend the rest of their lives. So, when the time comes, you have to consider pertinent things to help you make the right decisions. Levels Of Care Provided By The Assisted Living Facility Assisted living facilities offer varying levels of care which range from lower levels of care to memory care. Having an idea about the different levels of care provided in assisted living facilities will help you ask the right questions. You should be able to know what level best suits your loved one so that their needs can be addressed adequately. For instance, a person who only needs assistance with mobility but can do other things independently will be suited for level 1 care. On the other hand, those who need additional care because they have difficulty remembering things and can't take care of themselves will be better placed in level 3 care.
pharmacybiz

Alzheimer's:Next frontier for Novo Nordisk - 0 views

  •  
    Diabetes drugs that also promote weight loss such as Novo Nordisk's Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer's disease. Diabetes regimens, from Ozempic to old mainstays like insulin and metformin, appear to address several different aspects of the metabolic system implicated in Alzheimer's disease, including a protein called amyloid and inflammation, researchers say. The hope is that improving glucose utilisation and tamping down inflammation in the entire body - including the brain - could slow progression of debilitating diseases like Alzheimer's and Parkinson's. Several scientists interviewed by Reuters news agency pointed to mounting research supporting testing diabetes drugs against neurodegenerative diseases. Results are years away and success uncertain. But interest has been buoyed by recent positive data on Alzheimer's drugs developed by Eisai with partner Biogen and by Eli Lilly demonstrating that removing sticky amyloid plaques accumulated in the brain can slow cognition decline caused by the fatal mind-wasting disease. Those successes followed decades of futility that had left many questioning the validity of the amyloid theory behind most experimental Alzheimer's drugs.
pharmacybiz

Rehabilitation Clinic : Learn How To Flawlessly Operate - 0 views

  •  
    Drug addiction poses a serious challenge since it impacts one's physical and mental health. However, the good news is that individuals who complete a drug rehabilitation program can overcome this problem. If you are interested in providing rehab services, there are a couple of things you should know. Read on to learn how to operate a rehabilitation clinic flawlessly. KNOW THE NEEDS OF YOUR CLIENTS The main purpose of drug rehab is to help different people overcome addictions. It is designed to heal the body and mind from the negative effects of addiction. It also teaches the affected individuals to learn to live without using substances. Therefore, your first step is to conduct a comprehensive assessment of each client to formulate a personalized treatment plan. Everyone has unique needs in their recovery journey. Your rehab program can start with detox which is designed to rid the body of substances, although it does not treat addiction. The person affected undergoes different therapies during treatment. Therapy helps them deal with the issues that cause substance abuse and teach them healthier ways of life. Various therapies will be applied throughout the entire treatment process. Therefore, you must choose a suitable therapy for each individual. For instance, motivational interviewing and cognitive behavioral therapy are the most common.
pharmacybiz

Addiction Treatment : 6 Vital Things You Should Know About - 0 views

  •  
    Addiction is a complex disease that can be difficult to overcome. Many people don't realize how serious addiction is and often don't seek treatment until it's too late. If you or someone you know is struggling with addiction, it's important to learn as much as you can about the treatment process. This blog post will discuss six vital things that you should know about addiction treatment. RESEARCH THE VARIOUS TYPES OF TREATMENTS AVAILABLE One of the first things you should do when considering addiction treatment is to research the different types of treatments available. There are many different approaches to treating addiction, and it's important to find one that will work best for you or your loved one. Some common types of addiction treatments include 12-step programs, cognitive-behavioral therapy, detoxification, and medication-assisted treatment. The addiction treatment service providers behind Safe Harbor Treatment Center suggest that you should also consider the length of treatment, as some programs are more intensive than others. It's important to remember that no two people are the same, so what works for one person may not work for another. It's important to find a treatment that will address the underlying causes of addiction and help the individual to develop healthy coping mechanisms.
pharmacybiz

Parastou Donyai : RPS new chief scientist - 0 views

  •  
    The Royal Pharmaceutical Society (RPS) has appointed Professor Parastou Donyai as chief scientist. She will take up the role in June. Parastou is a pharmacist with a PhD in pharmacy. She also has a postgraduate diploma in Psychological Research Methods as well as a degree in Psychology. She is currently a professor of Social & Cognitive Pharmacy at the University of Reading and her research examines the psychology of medication use, discontinuation and decision-making processes. Prior to this, Parastou also spent more than five years as a senior lecturer in Pharmacy Practice at Kingston University and St. George's University of London. Her longstanding research interest includes continuing professional development in pharmacy. Commenting on her appointment, Parastou said: "It is a real privilege for me to be the Royal Pharmaceutical Society's next chief scientist. "As a pharmacist, scientist and academic, I look forward to working with the Royal Pharmaceutical Society's members and key stakeholders to uphold the value of science across the breadth of our profession."
pharmacybiz

Alzheimer disease : New insights on treatment - 0 views

  •  
    According to Alzheimer's Disease International, more than 55 million people worldwide will have Alzheimer's disease by 2020. This figure will nearly double every 20 years, reaching 78 million in 2030 and 139 million in 2050. The WHO Global Status Report for 2021 estimated the yearly global cost of dementia to be more than USD 1.3 trillion, with a projected increase to USD 2.8 trillion by 2030. To date most drugs developed to treat Alzheimer's disease have failed, largely because they target wrong biomarkers and individuals already exhibiting signs of the disease. Once symptoms appear, however, many brain cells responsible for memory and cognition are likely already damaged and beyond repair. Professor Shai Rahimipour in the Chemistry Department at Bar-Ilan University in Israel has pioneered a different approach utilizing theranostics to pinpoint and treat the earliest, pre-symptomatic signs of Alzheimer's disease. Showing promise in stopping progression of the disease before onset of irreversible brain cell damage, Rahimipour's groundbreaking approach has garnered significant attention in the scientific world.
pharmacybiz

Eisai :Files for approval of Alzheimer's drug in Europe - 0 views

  •  
    Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.
pharmacybiz

How Alcohol Harms Your Body Beyond Hangovers - 0 views

  •  
    Many of us drink alcohol on a regular basis, and when it comes to the weekend many of us have been known to overindulge a little. For the most part we understand the dangers of alcohol. We have an understanding that it can damage our liver, exacerbate mental health conditions and lead to addiction, with private alcohol treatment one of the few pathways to recovery. However, there are also many other effects that we may not be quite as familiar with, but it is important to know about them, particularly if you are a heavy drinker. Among some of the more common effects you may not be aware of, include… Disruption of REM Sleep Often we think alcohol gives us a better night's sleep, knocking us out for the count. However, while it does aid falling asleep, the quality of that sleep is significantly harmed. It disrupts the normal sleep cycle by reducing the time spent in rapid eye movement sleep, a stage that is important for memory consolidation and cognitive function. This sleep is less restorative and is why we often feel groggy and tired the following day.
pharmacybiz

NHS Gender Services: Critical Review Unveils Alarming Gaps - 0 views

  •  
    A final review of gender services provided by the NHS has uncovered significant shortcomings, leaving thousands of vulnerable children questioning their gender identity without adequate support. The report, led by Dr. Hilary Cass, a prominent consultant paediatrician, highlights the use of unproven treatments and the detrimental impact of the polarized trans debate on gender care provision. The investigation, commissioned by NHS England in 2020, focused on the Tavistock and Portman NHS mental health trust's gender identity development services (Gids), which treated around 9,000 children and young people between 2009 and 2020. Shockingly, the review found that despite limited evidence of effectiveness and potential health risks, puberty blockers and cross-sex hormones were routinely administered. Dr. Cass emphasized that the "rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health. The effect on cognitive and psychosexual development remains unknown."
pharmacybiz

Discover Tranquility: Exploring Green Tea Blends for Serenity | UK - 0 views

  •  
    Are you looking to infuse your day with tranquility and vitality? Look no further than the delicate and nuanced world of green tea blends. Whether you're a seasoned connoisseur or just dipping your toes into the vast ocean of tea, the artistry and serenity found in a well-crafted green tea blend are unmatched. Read on to discover the variety of green tea blends and how they can elevate your tea-drinking experience to new heights of relaxation and rejuvenation. Health Benefits: Nourishing Body and Mind Beyond their exquisite taste, green tea blends offer a myriad of health benefits that can nourish both body and mind. Packed with antioxidants and nutrients, green tea is known to boost metabolism, improve heart health, and enhance cognitive function. Green tea can contribute to helping you relax and unwind, while also providing a gentle energy boost to tackle your day with clarity and focus. Additionally, the ritual of preparing and savoring a cup of green tea can be a mindful practice that promotes relaxation and mental clarity.
healthingbee

Foods That Helps Improve Mental Health - 0 views

  •  
    You have probably read that eating certain food can lower the likelihood of high blood pressure and diabetes. How about your mental health? Are there any food that can improve your mental health and boost cognitive function? The answer is yes and here are some of the popular brain foods that are good for mental health.
1 - 18 of 18
Showing 20 items per page